JP2003300891A - Cerebral function ameliorating composition - Google Patents
Cerebral function ameliorating compositionInfo
- Publication number
- JP2003300891A JP2003300891A JP2002108290A JP2002108290A JP2003300891A JP 2003300891 A JP2003300891 A JP 2003300891A JP 2002108290 A JP2002108290 A JP 2002108290A JP 2002108290 A JP2002108290 A JP 2002108290A JP 2003300891 A JP2003300891 A JP 2003300891A
- Authority
- JP
- Japan
- Prior art keywords
- brain function
- improving composition
- egg yolk
- yolk plasma
- function improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Meat, Egg Or Seafood Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、脳機能改善組成物
に関する。TECHNICAL FIELD The present invention relates to a composition for improving brain function.
【０００２】[0002]
【従来の技術】近年の高齢化に伴い、記憶力の低下の防
止や学習能力の向上、即ち脳機能を改善することが重要
となってきている。2. Description of the Related Art With the recent aging of the population, it has become important to prevent deterioration of memory and improve learning ability, that is, improve brain function.
【０００３】これまでに学習能力を向上させる成分とし
てドコサヘキサエン酸（以下「ＤＨＡ」という）が広く
知られている。特開平１−２７９８２７号では、ＤＨＡ
がラットのＹ字迷路明暗弁別餌取り実験で正反応率を向
上させることが開示されている。しかしながら、ＤＨＡ
を食品等に添加する場合、独特の味や臭いがあるので、
その使用についてはいくつかの限定が余儀なくされてい
るのが現状である。Docosahexaenoic acid (hereinafter referred to as "DHA") has been widely known as a component for improving learning ability. Japanese Patent Application Laid-Open No. 1-279827 discloses DHA.
Has been disclosed to improve the positive reaction rate in a rat Y-shaped maze light / dark discrimination feeding experiment. However, DHA
When added to foods, etc., it has a unique taste and smell.
At present, some restrictions are imposed on its use.
【０００４】またフランスやドイツなどにおいては、イ
チョウ葉抽出エキスを有効成分とする治療薬が脳循環代
謝の改善を目的として広く使用されている。 ところ
が、イチョウ葉抽出エキスは、アルコールなどの有機溶
剤には溶解しても水には溶解し難いため、その使用につ
いて限定されるという問題点を有する。In France, Germany, etc., a therapeutic drug containing a ginkgo biloba extract as an active ingredient is widely used for the purpose of improving cerebral circulation metabolism. However, the ginkgo biloba extract has a problem that its use is limited because it is difficult to dissolve in water even if it is dissolved in an organic solvent such as alcohol.
【０００５】卵黄にはホスファチジルコリンやシアル酸
等の脳機能を改善する成分が多く含まれている。しかし
ながら、これらを含む画分を得る分離工程は煩雑であ
り、多大な設備投資が必要となる。また、これらを抽出
するためには、有機溶媒を使用する方法が一般的であ
る。しかし、有機溶媒は人体に有害であるものが多く、
これを除去する工程が必要である。さらに、このように
して得られた組成物は味が悪く、食品に有効量添加する
ことは困難である欠点を有する。また、卵黄自体からそ
の有効量摂取することは風味や食品加工上の問題などか
ら困難である。一方、塩化コリンを投与することによ
り、脳内のアセチルコリン濃度が上昇することが認めら
れているが、長時間持続しないため脳機能改善には適し
ていない。Egg yolk contains many components such as phosphatidylcholine and sialic acid that improve brain function. However, the separation process for obtaining the fraction containing these is complicated and requires a large capital investment. Moreover, in order to extract these, a method using an organic solvent is generally used. However, many organic solvents are harmful to the human body,
A step of removing this is required. Further, the composition thus obtained has a bad taste and has a drawback that it is difficult to add an effective amount to foods. In addition, it is difficult to ingest an effective amount of the egg yolk itself due to flavor and food processing problems. On the other hand, administration of choline chloride has been shown to increase the acetylcholine concentration in the brain, but it is not suitable for improving brain function because it does not last for a long time.
【０００６】以上のことにより、食品や医薬品に用いる
際に臭いや味に影響せず、安定供給可能な学習能力や記
憶等の、脳の機能を高める物質の開発が強く求められて
いた。In view of the above, there has been a strong demand for the development of substances that enhance brain functions such as learning ability and memory that can be stably supplied without affecting odor and taste when used in foods and pharmaceuticals.
【０００７】[0007]
【発明が解決しようとする課題】本発明は、有機溶媒や
カラム精製等の複雑な工程を経ることなく、従来の技術
では達成することができなかった風味のよい安定供給可
能な脳機能改善組成物を提供することを目的とする。DISCLOSURE OF THE INVENTION The present invention does not require complicated steps such as organic solvent and column purification, and has a savory and stable supply of brain functions which could not be achieved by conventional techniques. The purpose is to provide things.
【０００８】[0008]
【課題を解決するための手段】本発明者らは、複雑な工
程を経ることなく、風味の良い脳機能改善組成物を供す
る観点から鋭意研究した結果、卵黄プラズマの浮上画分
が上記の課題を解決することを見出し、本発明を完成さ
せるに至った。すなわち本発明は、卵黄プラズマの浮上
画分を有効成分として含有することを特徴とする脳機能
改善組成物を提供するものである。Means for Solving the Problems The inventors of the present invention have earnestly studied from the viewpoint of providing a savory composition for improving brain function without going through complicated steps, and as a result, the floating fraction of egg yolk plasma has the above-mentioned problems. The present invention has been completed and the present invention has been completed. That is, the present invention provides a brain function-improving composition, characterized in that it contains a floating fraction of yolk plasma as an active ingredient.
【０００９】[0009]
【発明の実施の形態】本発明における脳機能改善とは、
痴呆症予防及び治療、アルツハイマー症の予防及び治
療、及び学習能力の向上及び改善の１種又は２種以上を
指す。BEST MODE FOR CARRYING OUT THE INVENTION Improvement of brain function in the present invention means
It refers to one or more of prevention and treatment of dementia, prevention and treatment of Alzheimer's disease, and improvement and improvement of learning ability.
【００１０】本発明における脳機能改善組成物は、小児
期又は中高齢期を中心に脳機能改善のために使用される
食品、医薬品及び医薬部外品に添加して使用できるが、
単独で摂取することもでき、その使用形態は特に限定さ
れない。The brain function improving composition of the present invention can be used by adding it to foods, pharmaceuticals and quasi drugs used for improving brain function mainly in childhood or middle aged.
It can be ingested alone, and its use form is not particularly limited.
【００１１】本発明における卵黄は、特に限定するもの
ではないが、通常、鳥類の卵より得られるものを指し、
原料の確保の観点から、鶏卵の卵黄が好ましい。又、本
発明に用いる卵黄は、殻付き卵を割卵後、卵白を分離し
た卵黄液、加塩卵黄、加糖卵黄及び卵黄粉末の１種又は
２種以上であるが、卵黄プラズマ浮上画分を効率的に得
る観点から、卵黄液が好ましい。卵黄は、脂質と蛋白質
が結合した低密度リポ蛋白質（以下「ＬＤＬ」という）
及び高密度リポ蛋白質（以下「ＨＤＬ」という）、及び
リベチンとホスビチン等の水溶性蛋白質が主要な構成成
分である。The egg yolk in the present invention is not particularly limited, but usually refers to one obtained from an avian egg,
From the viewpoint of securing raw materials, egg yolk of chicken eggs is preferable. The egg yolk used in the present invention is one or more of egg yolk liquid, salted egg yolk, sweetened egg yolk and egg yolk powder obtained by breaking the shell eggs and separating the egg white, but the yolk plasma levitating fraction is efficiently used. The egg yolk liquid is preferable from the viewpoint of obtaining it in a desired manner. Egg yolk is a low density lipoprotein (hereinafter referred to as "LDL") in which lipid and protein are bound.
High density lipoprotein (hereinafter referred to as “HDL”), and water-soluble proteins such as ribetin and phosvitin are major constituents.
【００１２】本発明の卵黄プラズマとは、卵黄に加水し
た後、遠心分離して得られた上清部分を指し、その加水
条件や遠心分離の条件は特に限定されない。卵黄を遠心
分離すると、それぞれの成分の密度、すなわち、脂質と
蛋白質の存在割合により、沈殿成分と上清成分に分離す
る。沈殿成分は卵黄グラニュ−ルと呼ばれ、主にＨＤＬ
とホスビチンの複合体から成る。上清成分が卵黄プラズ
マと呼ばれ、主にＬＤＬとリベチンから成る。卵黄プラ
ズマの調製方法は、公知の方法を利用すればよく、卵黄
を等量〜１６倍量、好ましくは２倍量〜８倍量の水もし
くは生理的食塩水で希釈し分離することにより、沈殿の
卵黄グラニュールと上清の卵黄プラズマに分離できる。
遠心分離の条件は特に限定するものではないが、遠心加
速度は３，０００〜２４，０００Ｇ、好ましくは６，０
００〜１０，０００Ｇである。本発明に用いる遠心機は
冷却高速遠心機、卓上遠心機、連続高速遠心機及び円筒
型超遠心分離機等であり、特に限定されないが、高い遠
心加速度が得られることから、円筒型超遠心分離機が好
ましい。The egg yolk plasma of the present invention refers to the supernatant obtained by centrifuging the egg yolk, and the watering conditions and centrifugation conditions are not particularly limited. When egg yolk is centrifuged, it is separated into a precipitate component and a supernatant component depending on the density of each component, that is, the proportion of lipid and protein present. Precipitated components are called egg yolk granules and are mainly HDL
And phosvitin complex. The supernatant component is called egg yolk plasma and mainly consists of LDL and ribetin. The egg yolk plasma may be prepared by a known method, for example, by diluting the egg yolk with an equal amount to 16 times, preferably from 2 times to 8 times the amount of water or physiological saline to separate the yolk. Can be separated into egg yolk granules and supernatant yolk plasma.
The conditions for centrifugation are not particularly limited, but the centrifugal acceleration is 3,000 to 24,000 G, preferably 6,0.
It is 00-10,000G. The centrifuge used in the present invention is a cooling high-speed centrifuge, a table-top centrifuge, a continuous high-speed centrifuge, a cylindrical ultracentrifuge, or the like, and is not particularly limited, but a high-speed centrifugal acceleration can be obtained, so that the cylindrical ultracentrifuge Machine is preferred.
【００１３】本発明の卵黄プラズマ浮上画分とは、卵黄
プラズマに加水した際に浮上してくる画分であれば特に
限定するものではないが、例えば卵黄プラズマのｐＨを
５．５〜７．５に調整後、水又は生理的食塩水を、２〜
１６倍量添加することで浮上してくる画分を指す。卵黄
プラズマ浮上画分の密度は０．９０〜１．０２ｇ／ｃｍ
３、好ましくは０．９５〜０．９９ｇ／ｃｍ３である。The yolk plasma levitating fraction of the present invention is not particularly limited as long as it is a fraction that floats up when water is added to the yolk plasma. For example, the pH of the yolk plasma is 5.5 to 7. After adjusting to 5, water or physiological saline, 2 ~
It refers to the fraction that emerges when 16 times the amount is added. The density of the yolk plasma floating fraction is 0.90 to 1.02 g / cm
3 , preferably 0.95 to 0.99 g / cm 3 .
【００１４】本発明の卵黄プラズマ浮上画分は、通常、
水分が４０〜６０重量％含まれており、水分を除いた固
形分中には蛋白質を５〜２５重量％、好ましくは１０〜
２０重量％含有している。また、脂質を７０〜９５重量
％、好ましくは８０〜９０重量％含有している。The egg yolk plasma levitating fraction of the present invention is usually
The water content is 40 to 60% by weight, and the solid content excluding water contains 5 to 25% by weight of protein, preferably 10 to 50% by weight.
It contains 20% by weight. It also contains 70 to 95% by weight of lipid, preferably 80 to 90% by weight.
【００１５】本発明の卵黄プラズマ浮上画分の固形分中
には、アポビテレニンを１〜２０重量％、好ましくは２
〜１５重量％含んでいる。アポビテレニンはポリペプチ
ドで構成されており、分子量１２０，０００〜１８０，
０００のポリペプチドを６０〜８０重量％含んでいる。
アポビテレニンは、卵黄プラズマ浮上画分を通常の方
法、例えばクロロホルム−メタノール（２：１）などで
脱脂し、凍結乾燥して得られる画分に存在する性質を有
する。又、水性緩衝液に不溶であり、尿素又はドデシル
硫酸ナトリウム（ＳＤＳ）等の界面活性剤に溶解する性
質を有する。アポビテレニンの検出方法は公知の方法を
利用すればよく、例えば０．５％ＳＤＳ溶液に溶解後、
ＳＤＳポリアクリルアミドゲル電気泳動やゲルろ過など
により、分子量に応じた特有のバンド及びピークを確認
することができ、得られたピークの蛋白質含量を測定す
ることにより定量することが可能である。また、電気泳
動された蛋白質をニトロセルロース膜上に転写し、転写
させた蛋白質に、ウサギより得たアポビテレニンのＩｇ
Ｇの一次抗体を作用させ、ペルオキシターゼ標識ヤギ抗
ウサギＩｇＧ等を二次抗体として用いたウエスタンブロ
ット法によりアポビテレニンを検出することが可能であ
る。The solid content of the egg yolk plasma floatation fraction of the present invention contains 1 to 20% by weight of apoviterenin, preferably 2%.
~ 15% by weight. Apobiterenin is composed of a polypeptide and has a molecular weight of 120,000 to 180,
000 polypeptides of 60-80% by weight.
Apobiterenin has the property of being present in the fraction obtained by defatting the yolk plasma floating fraction by a conventional method, for example, chloroform-methanol (2: 1), and freeze-drying. Further, it is insoluble in an aqueous buffer solution and has a property of being dissolved in a surfactant such as urea or sodium dodecyl sulfate (SDS). As a method for detecting apobiterenin, a known method may be used. For example, after dissolving in a 0.5% SDS solution,
By SDS polyacrylamide gel electrophoresis, gel filtration, etc., a specific band and peak corresponding to the molecular weight can be confirmed, and it can be quantified by measuring the protein content of the obtained peak. In addition, the electrophoresed protein was transferred onto a nitrocellulose membrane, and the apoviterenin Ig obtained from rabbit was transferred to the transferred protein.
It is possible to detect apoviterenin by Western blotting using a primary antibody of G and a goat anti-rabbit IgG labeled with peroxidase as a secondary antibody.
【００１６】本発明の卵黄プラズマ浮上画分の調製方法
は、卵黄プラズマをｐＨ５．５〜７．５、好ましくはｐ
Ｈ６．２〜６．８に調整することにより得ることができ
る。本発明では、浮上画分を分離させる放置温度や時間
は卵黄プラズマ希釈液が腐敗しない条件であれば良く、
一般的には、液温が１０〜３０℃の場合は２〜３時間、
好ましくは１０℃以下では２〜２４時間放置すること
で、卵黄プラズマの上層に黄色い粘性物が浮上した卵黄
プラズマ浮上画分を得ることができる。また、卵黄プラ
ズマのｐＨを５．５〜７．５に調整後、遠心分離機によ
り３，０００〜２４，０００Ｇ、好ましくは３，０００
〜８，０００Ｇの遠心加速度で分離し、浮上画分を得る
方法を用いてもよい。実用的な面を考慮すると遠心分離
機を用いて分離することが好ましい。The method of preparing the yolk plasma levitating fraction of the present invention uses egg yolk plasma at a pH of 5.5 to 7.5, preferably p.
It can be obtained by adjusting to H6.2 to 6.8. In the present invention, the standing temperature and time for separating the floating fraction may be any conditions that do not spoil the yolk plasma diluted solution,
Generally, when the liquid temperature is 10 to 30 ° C, it takes 2 to 3 hours,
Preferably, by leaving it at 10 ° C. or lower for 2 to 24 hours, a yolk plasma floating fraction in which a yellow viscous substance floats on the upper layer of the yolk plasma can be obtained. In addition, after adjusting the pH of egg yolk plasma to 5.5 to 7.5, it is centrifuged at 3,000 to 24,000 G, preferably 3,000.
A method of obtaining a floating fraction by separating at a centrifugal acceleration of up to 8,000 G may be used. From a practical point of view, it is preferable to separate using a centrifuge.
【００１７】本発明の脳機能改善組成物は、上述の方法
などにより得られた卵黄プラズマ浮上画分、又は、これ
を凍結乾燥、噴霧乾燥等の通常の乾燥方法で粉末状にし
たものを含有している組成物を指す。本発明の脳機能改
善組成物は、そのままの状態又は粉末化したものを、食
品、医薬品及び医薬部外品などに添加し、摂取すること
ができる。The brain function-improving composition of the present invention contains the egg yolk plasma floating fraction obtained by the above-mentioned method or the like, or the powdered product obtained by an ordinary drying method such as freeze-drying or spray-drying. Refers to the composition. The brain function improving composition of the present invention can be ingested as it is or in a powdered form by adding it to foods, pharmaceuticals, quasi drugs and the like.
【００１８】本発明における卵黄プラズマ浮上画分の摂
取量は、健康状態、年齢、体重、性別などにより異なる
が、成人で卵黄プラズマ浮上画分を固形分として、１日
あたり１０ｍｇ〜５０ｇ、好ましくは１００ｍｇ〜２０
ｇを適宜増減して、単回又は複数回に分けて、摂取すれ
ばよい。これはアポビテレニン量換算において、０．１
ｍｇ〜１０ｇに相当する。The intake amount of the yolk plasma levitating fraction in the present invention varies depending on the health condition, age, weight, sex, etc., but is 10 mg to 50 g per day, preferably the egg yolk plasma levitating fraction as a solid content in adults. 100 mg to 20
The g may be appropriately increased or decreased to be ingested in a single dose or in multiple doses. This is 0.1 in terms of the amount of apobiterenin.
Equivalent to mg to 10 g.
【００１９】以下、本発明を実施例をあげて具体的に説
明するが、本発明はこれらによって何等限定されるもの
ではない。Hereinafter, the present invention will be specifically described with reference to examples, but the present invention is not limited thereto.
【００２０】[0020]
【実施例】実施例１
卵黄１００ｇに水２００ｇを加え、攪拌後、卓上遠心分
離機を用いて遠心分離し（遠心加速度８，０００Ｇ、時
間３０分間）、卵黄プラズマ２４５ｇと卵黄グラニュー
ル５５ｇを得た。次いで卵黄プラズマを１．０Ｎ水酸化
ナトリウム水溶液によってｐＨ６．８に調整後、８倍量
に相当する水１９８０ｇを添加し、卓上遠心分離機によ
り遠心分離し（遠心加速度３，０００Ｇ、時間１５分
間）、卵黄プラズマ浮上画分を６０ｇを得た。卵黄プラ
ズマ浮上画分を凍結乾燥して、本発明の脳機能改善組成
物を２８ｇを得た。得られた本発明品を分析した結果、
脂質含量８６重量％、蛋白質含量は１３重量％であっ
た。また、アポビテレニン含量は１０．２重量％であっ
た。Example 1 200 g of water was added to 100 g of egg yolk, and after stirring, centrifugation was performed using a tabletop centrifuge (centrifugal acceleration 8,000 G, time 30 minutes) to obtain 245 g of yolk plasma and 55 g of egg yolk granules. It was Next, the egg yolk plasma was adjusted to pH 6.8 with a 1.0 N sodium hydroxide aqueous solution, then 1980 g of water corresponding to 8 times the amount was added, and the mixture was centrifuged with a tabletop centrifuge (centrifugal acceleration 3,000 G, time 15 minutes). Then, 60 g of the yolk plasma floating fraction was obtained. The yolk plasma floating fraction was freeze-dried to obtain 28 g of the brain function improving composition of the present invention. As a result of analyzing the obtained product of the present invention,
The lipid content was 86% by weight and the protein content was 13% by weight. The apoviterenin content was 10.2% by weight.
【００２１】実施例２
殺菌液卵黄１０ｋｇに水４０ｋｇを加え撹拌した。次い
で、連続高速遠心分離機により連続遠心分離し（６，０
００Ｇ）、卵黄プラズマ４７ｋｇと卵黄グラニュール３
ｋｇを分離した。得られた卵黄プラズマ（ｐＨ６．２）
に水１８８ｋｇを加えて、もとの卵黄重量に対して１０
倍になるよう希釈し、１．０Ｎ水酸化ナトリウムを用い
ｐＨを７に調整した後、５〜１０℃で１６時間放置し
た。液面の浮上物をすくい取って回収し、本発明の脳機
能改善組成物を４．５ｋｇを得た。得られた本発明品を
凍結乾燥し、分析した結果、脂質含量８３重量％、蛋白
質含量は１５重量％であった。また、アポビテレニン含
量は８重量％であった。水分は５６％であった。Example 2 40 kg of water was added to 10 kg of sterilized egg yolk and stirred. Then, a continuous high-speed centrifuge is used for continuous centrifugation (6,0
00G), 47kg yolk plasma and 3 yolk granules
kg was separated. Obtained yolk plasma (pH 6.2)
Add 188 kg of water to 10% of the original yolk weight
The mixture was diluted to double the pH, adjusted to pH 7 with 1.0 N sodium hydroxide, and then left standing at 5 to 10 ° C. for 16 hours. The floating material on the liquid surface was scooped up and collected to obtain 4.5 kg of the brain function improving composition of the present invention. The obtained product of the present invention was freeze-dried and analyzed, and as a result, the lipid content was 83% by weight and the protein content was 15% by weight. The apoviterenin content was 8% by weight. The water content was 56%.
【００２２】実施例３
卵黄６００ｋｇに脱イオン水２４００ｋｇを加え攪拌し
た。次いで、円筒型超遠心分離機（巴工業株式会社製
ＡＳＭ１６０型）に２５０Ｌ／ｈの処理速度で通液する
ことにより、卵黄プラズマ２３００ｋｇと卵黄グラニュ
ール９０ｋｇを得た。得られた卵黄プラズマ２３００ｋ
ｇを０．１Ｎ水酸化ナトリウムを用いｐＨを６．５に調
整した後、脱イオン水を９２００ｋｇ加えて、５〜１５
℃で１６時間放置した。液面の浮上物をすくい取って回
収し、本発明の脳機能改善組成物を１８０ｋｇを得た。
得られた本発明品を凍結乾燥し、分析した結果、脂質含
量８０重量％、蛋白質含量は１５重量％であった。ま
た、アポビテレニン含量は８重量％であった。水分は５
６重量％であった。Example 3 To 600 kg of egg yolk, 2400 kg of deionized water was added and stirred. Then, a cylindrical ultracentrifuge (made by Tomoe Kogyo Co., Ltd.)
2300 kg of egg yolk plasma and 90 kg of egg yolk granules were obtained by passing the solution through ASM160 type) at a treatment rate of 250 L / h. The obtained yolk plasma 2300k
After adjusting the pH to 6.5 with 0.1 N sodium hydroxide, 9200 kg of deionized water was added,
It was left at 16 ° C for 16 hours. The floating material on the liquid surface was scooped up and collected to obtain 180 kg of the brain function improving composition of the present invention.
The obtained product of the present invention was freeze-dried and analyzed, and as a result, the lipid content was 80% by weight and the protein content was 15% by weight. The apoviterenin content was 8% by weight. Water is 5
It was 6% by weight.
【００２３】 実施例４ 牛乳 １８０ｇ 脳機能改善組成物（実施例２より得たもの） ３６ｇ 全卵 ３０ｇ グラニュー糖 ４０ｇ バニラエッセンス ０．２ｇ ラム酒 ４ｇ[0023] Example 4 180g milk Brain function improving composition (obtained from Example 2) 36 g 30g whole egg Granulated sugar 40g Vanilla essence 0.2g 4 g of rum
【００２４】上記記載の配合表に従い、蒸しプリンを調
製した。即ち、脳機能改善組成物と全卵を混ぜ合わせ、
砂糖を混合した。牛乳を添加し、さらに混ぜ合わせ、バ
ニラエッセンス及びラム酒を添加した。得られたものを
ガーゼで濾した後、容器に入れ蒸し器で蒸した。蒸しあ
がったプリンは風味がよいものであった。Steamed pudding was prepared according to the above-mentioned recipe. That is, the brain function improving composition and whole egg are mixed,
Mixed with sugar. Milk was added, mixed further and vanilla extract and rum added. The obtained product was filtered with gauze, put in a container, and steamed with a steamer. The steamed pudding had a good flavor.
【００２５】試験例１
若齢ラットとしてウィスター系雄ラット（５週齢）を、
老齢ラットとしてウィスター系雄ラット（８０週齢）を
各１０匹それぞれ用いた。若齢ラットは２種類の飼料を
各々与えるべく２群を設定した。老齢ラットは３種類の
飼料を各々与えるべく３群を設定した。各群に与える飼
料の配合を表１に示す。Test Example 1 Male Wistar rats (5 weeks old) were used as young rats.
Ten Wistar male rats (80 weeks old) were used as aged rats. Two groups of young rats were set up to receive two kinds of feeds respectively. Aged rats were set up in 3 groups to receive 3 kinds of feeds respectively. Table 1 shows the composition of the feed given to each group.
【００２６】[0026]
【表１】 [Table 1]
【００２７】それぞれの群を各飼料で１０週間飼育した
後、モーリス水迷路（Ｊ． Ｎｅｕｒｏｓｃｉ．Ｍｅｔ
ｈ．，１１，ｐ．４７−６０，１９８４）を用いた学習
・記憶能力に関する水迷路試験を行った。すなわち、円
形のプール（直径１８０ｃｍ、深さ７０ｃｍ）に円形の
プラットホーム（直径２０ｃｍ、高さ３０ｃｍ）を置
き、プラットホームの面が隠れるようにプラットホーム
の上２ｃｍまで水を入れた。各ラットを毎回異なったス
タート位置から遊泳させ、プラットホーム上でラットが
５秒以上止まるまでの時間（Ｅｓｃａｐｅ Ｌａｔｅｎ
ｃｙ：ＥＬ）を測定した。ＥＬの測定時間は最大９０秒
とし、この試験を１日１回、計１０日間（１０回）行っ
た。９０秒以内にプラットホームに上がったラットの比
率を図１及び表２に、プラットホーム上でラットが５秒
以上止まるまでの時間（ＥＬ）を図２及び表３にそれぞ
れ示した。After each group was fed with each feed for 10 weeks, the Morris water maze (J. Neurosci. Met) was used.
h. , 11, p. 47-60, 1984) was used to conduct a water maze test on learning and memory abilities. That is, a circular platform (diameter 20 cm, height 30 cm) was placed in a circular pool (diameter 180 cm, depth 70 cm), and water was poured up to 2 cm above the platform so that the surface of the platform was hidden. Each rat was allowed to swim from a different starting position each time, and the time it took for the rat to remain on the platform for 5 seconds or longer (Escape Laten
cy: EL) was measured. The EL measurement time was 90 seconds at maximum, and this test was performed once a day for a total of 10 days (10 times). The proportion of rats that rose to the platform within 90 seconds is shown in FIG. 1 and Table 2, and the time (EL) until the rat stopped for 5 seconds or more on the platform is shown in FIG. 2 and Table 3, respectively.
【００２８】上記水迷路試験において、各群のラットい
ずれもが９０秒以内にプラットホームに達する割合は試
験を重ねる毎に高い値を示し、また、プラットホーム上
でラットが５秒以上止まるまでの時間は試験を重ねる毎
に短縮していることから、すべての試験群でプラットホ
ームに上がることにより水から逃れられる事を学習し、
それを記憶していることが確認された。若齢ラットの脳
機能改善組成物フリー食摂取群（ＹＦ群）は、老齢ラッ
トの脳機能改善組成物フリー食摂取群（Ｆ群）に比べて
９０秒以内にプラットホームに達する割合は有意に高
く、プラットホーム上でラットが５秒以上止まるまでの
時間は有意に短縮していた。これは加齢により学習記憶
能が低下することによるものと考えられる。In the above water maze test, the rate at which all the rats in each group reach the platform within 90 seconds shows a high value each time the test is repeated, and the time until the rat stops on the platform for 5 seconds or more is Since it shortens with each test, learn to escape from water by climbing to the platform in all test groups,
It was confirmed to remember it. The rate of reaching the platform within 90 seconds in the brain function improving composition-free food intake group (YF group) of young rats is significantly higher than that in the old brain function improving composition-free food intake group (F group). , The time until the rat stopped on the platform for 5 seconds or more was significantly shortened. It is considered that this is due to a decline in learning and memory with age.
【００２９】老齢ラットにおいて比較すると、脳機能改
善組成物含有食摂取群（Ｂ群）は、脳機能改善組成物フ
リー食摂取群（Ｆ群）と比べて、９０秒以内にプラット
ホームに達する割合は有意に高く、プラットホーム上で
ラットが５秒以上止まるまでの時間も有意に短縮してお
り、学習・記憶能が改善していることが認められた。さ
らにＤＨＡ含有食摂取群（Ｄ群）においても学習・記憶
能の改善効果が認められたが、脳機能改善組成物含有食
摂取群で得られた結果以上の効果は観察されなかった。
また、若齢ラットにおいて比較すると、若齢ラットの脳
機能改善組成物含有食摂取群（ＹＢ群）は、若齢ラット
の脳機能改善組成物フリー摂取群（ＹＦ群）に比べて、
９０秒以内にプラットホームに達する割合は高く、プラ
ットホーム上でラットが５秒以上止まるまでの時間も短
縮しており、学習・記憶能が改善していることが認めら
れた。When compared with aged rats, the proportion of the group of foods containing the brain function improving composition (group B), which reached the platform within 90 seconds, was higher than that of the group of foods containing brain function improving composition-free foods (group F). It was significantly high, and the time required for the rat to stop on the platform for 5 seconds or more was significantly shortened, and it was confirmed that the learning / memory ability was improved. Further, the effect of improving learning and memory ability was also observed in the DHA-containing food intake group (D group), but no effect more than the result obtained in the brain function improving composition-containing food intake group was observed.
Further, when compared in young rats, the brain function improving composition-containing food intake group (YB group) of the young rats is compared with the brain function improving composition free intake group (YF group) of the young rats,
It was confirmed that the ratio of reaching the platform within 90 seconds was high, the time for the rat to stop on the platform for 5 seconds or more was shortened, and the learning / memory ability was improved.
【００３０】[0030]
【表２】 [Table 2]
【００３１】[0031]
【表３】 [Table 3]
【００３２】試験例２
５０〜７０歳の老人３０名対し、実施例２で得られた本
発明の脳機能改善組成物を３．０ｇ／日ずつ与えて、記
憶力の評価を行った。評価方法はＴ．Ｃｒｏｏｋ等が考
案したＭＡＣ法（Ｎｅｕｒｏｌｏｇｙ，４１，ｐ．６４
４−４９，１９９１）を用いた。ＭＡＣ法は、人の顔と
名前を記憶すること、電話番号を記憶すること、買い物
リストを記憶することなどの日常の記憶力について試験
し評価する方法である。ＭＡＣ法を用いて記憶年齢を算
出したところ、試験開始時は平均６２．６歳であった
が、投与開始から３週間後には、５４．３歳となった。
以上のことより、記憶力の低下について効果が認められ
た。Test Example 2 To 30 elderly persons aged 50 to 70 years old, the brain function improving composition of the present invention obtained in Example 2 was given 3.0 g / day, and the memory ability was evaluated. The evaluation method is T.I. MAC method devised by Crook et al. (Neurology, 41, p. 64)
4-49, 1991) was used. The MAC method is a method of testing and evaluating daily memory abilities such as memorizing a person's face and name, memorizing a telephone number, and memorizing a shopping list. When the memory age was calculated using the MAC method, the average was 62.6 years at the start of the test, but it was 54.3 years after 3 weeks from the start of administration.
From the above, an effect was recognized for the reduction of memory.
【００３３】試験例３
軽度から中等度の痴呆患者２６名に対し、実施例２で得
られた脳機能改善組成物を５．０ｇ／日ずつ与え、痴呆
診断テストを行った。評価方法は、長谷川式簡易知能評
価に従った。長谷川式簡易知能評価は、年齢や場所を尋
ねたり、簡単な言葉を記憶させることなどにより評価す
る方法であり、テストのスコアが高いほど、痴呆の程度
が軽いことを表す。投与前と投与後の痴呆患者のテスト
スコアの平均は、投与前では１４．６点であったもの
が、投与後に１８．５点になった（３０満点）。このこ
とより、投与前に比較して、明らかに痴呆の程度の改善
が認められた。Test Example 3 The dementia diagnosis test was carried out on 26 dementia patients with mild to moderate dementia by giving the brain function improving composition obtained in Example 2 at 5.0 g / day. The evaluation method was based on the Hasegawa simple intelligence evaluation. The Hasegawa-type simplified intelligence evaluation is a method of evaluating by asking the age and place or memorizing simple words, and the higher the test score, the lower the degree of dementia. The average test score of the demented patients before and after administration was 14.6 points before administration, but became 18.5 points after administration (30 points full). From this, the degree of dementia was clearly improved as compared with that before administration.
【００３４】本発明の実施態様をあげれば以下の通りで
ある。
（１）卵黄プラズマ浮上画分を含有することを特徴とす
る脳機能改善組成物。
（２）卵黄プラズマ浮上画分が鶏卵卵黄由来であること
を特徴とする前記（１）記載の脳機能改善組成物。
（３）卵黄プラズマ浮上画分が、卵黄プラズマを水又は
塩溶液で希釈し、放置することで得られることを特徴と
する前記（１）及び（２）いずれか記載の脳機能改善組
成物。
（４）卵黄プラズマ浮上画分が、卵黄プラズマの水又は
塩溶液の希釈液を遠心分離して得られることを特徴とす
る前記（１）〜（３）いずれか記載の脳機能改善組成
物。
（５）卵黄プラズマ浮上画分が、卵黄プラズマの水又は
塩溶液の希釈液を３，０００〜２４，０００Ｇの遠心条
件で遠心分離して得られることを特徴とする前記（１）
〜（４）いずれか記載の脳機能改善組成物。
（６）卵黄プラズマ浮上画分が、卵黄プラズマの水又は
塩溶液の希釈液をｐＨ５．５〜７．５に調整することに
より得ることができる前記（１）〜（５）いずれか記載
の脳機能改善組成物。
（７）アポビテレニンが卵黄プラズマ浮上画分に含有さ
れることを特徴とする前記（１）〜（６）いずれか記載
の脳機能改善組成物。
（８）卵黄プラズマ浮上画分の固形分中にアポビテレニ
ンを１〜２０重量％含むことを特徴とする前記（１）〜
（７）いずれか記載の脳機能改善組成物。The embodiments of the present invention are as follows. (1) A brain function improving composition comprising an egg yolk plasma floating fraction. (2) The brain function improving composition as described in (1) above, wherein the egg yolk plasma floating fraction is derived from chicken egg yolk. (3) The brain function improving composition according to any one of (1) and (2) above, wherein the yolk plasma floating fraction is obtained by diluting the yolk plasma with water or a salt solution and leaving it to stand. (4) The brain function improving composition according to any one of (1) to (3) above, wherein the yolk plasma floating fraction is obtained by centrifugation of a diluted solution of egg yolk plasma water or a salt solution. (5) The yolk plasma floating fraction is obtained by centrifuging a diluted solution of egg yolk plasma water or a salt solution under centrifugation conditions of 3,000 to 24,000 G. (1)
~ The brain function improving composition according to any one of (4). (6) The brain of any one of (1) to (5) above, wherein the yolk plasma floating fraction can be obtained by adjusting the pH of the yolk plasma water or salt solution to a pH of 5.5 to 7.5. Function improving composition. (7) The brain function improving composition according to any one of (1) to (6) above, wherein apoviterenin is contained in the yolk plasma floating fraction. (8) The above-mentioned (1) -wherein the solid content of the yolk plasma floating fraction contains 1 to 20% by weight of apoviterenin.
(7) The brain function improving composition according to any one of the above.
【００３５】（９）アポビテレニンを含むポリペプチド
の分子量が１２０，０００〜１８０，０００であること
を特徴とする前記（１）〜（８）いずれか記載の脳機能
改善組成物。
（１０）脳機能改善が痴呆症予防及び治療、アルツハイ
マー症の予防及び治療、及び学習能力の向上及び改善の
１種又は２種以上であることを特徴とする前記（１）〜
（９）いずれか記載の脳機能改善組成物。
（１１）脳機能改善が学習能力向上であることを特徴と
する前記（１）〜（９）いずれか記載の脳機能改善組成
物。
（１２）脳機能改善が学習能力の改善であることを特徴
とする前記（１）〜（９）いずれか記載の脳機能改善組
成物。
（１３）脳機能改善が記憶力の向上である前記（１）〜
（９）いずれか記載の脳機能改善組成物。
（１４）脳機能改善が記憶力の改善である前記（１）〜
（９）いずれか記載の脳機能改善組成物。
（１５）脳機能改善が痴呆症の治療である前記（１）〜
（９）いずれか記載の脳機能改善組成物。
（１６）脳機能改善が痴呆症の予防である前記（１）〜
（９）いずれか記載の脳機能改善組成物。
（１７）脳機能改善がアルツハイマー症の治療である前
記（１）〜（９）いずれか記載の脳機能改善組成物。
（１８）脳機能改善がアルツハイマー症の予防である前
記（１）〜（９）いずれか記載の脳機能改善組成物。
（１９）アポビテレニンを含有することを特徴とする脳
機能改善組成物。(9) The brain function improving composition as described in any one of (1) to (8) above, wherein the polypeptide containing apobiterenin has a molecular weight of 120,000 to 180,000. (10) The brain function improvement is one or more of prevention and treatment of dementia, prevention and treatment of Alzheimer's disease, and improvement and improvement of learning ability, (1) to
(9) The brain function improving composition according to any one of the above. (11) The brain function improving composition according to any one of (1) to (9), wherein the brain function improving is learning ability improving. (12) The brain function improving composition according to any one of (1) to (9), wherein the brain function improvement is improvement of learning ability. (13) The improvement of brain function is improvement of memory ability (1) to
(9) The brain function improving composition according to any one of the above. (14) The improvement of brain function is improvement of memory ability (1) to
(9) The brain function improving composition according to any one of the above. (15) The improvement of brain function is the treatment of dementia (1) to
(9) The brain function improving composition according to any one of the above. (16) The improvement of brain function is prevention of dementia (1) to
(9) The brain function improving composition according to any one of the above. (17) The brain function improving composition according to any one of (1) to (9), wherein the brain function improvement is treatment of Alzheimer's disease. (18) The brain function improving composition according to any one of (1) to (9), wherein the brain function improvement is prevention of Alzheimer's disease. (19) A brain function improving composition containing apobiterenin.
【００３６】[0036]
【発明の効果】本発明の脳機能改善組成物を摂取させる
ことにより、記憶力の改善や学習能力の改善に効果が認
められる。EFFECTS OF THE INVENTION By ingesting the brain function improving composition of the present invention, an effect is recognized in improving memory and learning ability.
【００３７】従って、本発明の脳機能改善組成物は、学
習能力の向上や記憶力の低下の改善などを目的とした食
品の原料や医薬品などとして好適であることが明らかに
なった。Therefore, it was revealed that the brain function improving composition of the present invention is suitable as a raw material of foods, pharmaceuticals and the like for the purpose of improving learning ability and memory deterioration.
【００３８】[0038]
【図１】図１は、水迷路試験において、９０秒以内にプ
ラットホームに上がったラットの比率を示したものであ
る。横軸は遊泳試行回数を、縦軸はプラットホームに上
がったラットの比率を示す。図中、◆は老齢ラットの脳
機能改善組成物フリー食摂取群（Ｆ群）、■は老齢ラッ
トの脳機能改善組成物摂取群（Ｂ群）をそれぞれ示す
（図２も同様）。FIG. 1 shows the proportion of rats that went up to the platform within 90 seconds in the water maze test. The horizontal axis shows the number of swimming trials, and the vertical axis shows the ratio of the rats who went up to the platform. In the figure, ◆ indicates a group of the aged rat brain function-improving composition-free food intake group (F group), and ■ indicates a group of aged rat brain function-improving composition intake group (group B) (the same applies to FIG. 2).
【図２】図２は、水迷路試験において、プラットホーム
上でラットが５秒以上止まるまでの時間を示したもので
ある。横軸は遊泳試行回数、縦軸は各群のＥＬを示す。FIG. 2 shows the time required for a rat to stop on a platform for 5 seconds or more in a water maze test. The horizontal axis shows the number of swimming trials, and the vertical axis shows the EL of each group.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 山崎 長宏 三重県四日市市赤堀新町９番５号 太陽化 学株式会社内 Ｆターム(参考） 4B018 LB01 MD72 ME10 ME14 MF01 4B042 AC04 AD40 AG06 AG07 AH10 AP15 4C084 AA01 AA02 BA44 CA41 DC50 MA52 NA02 NA09 NA14 ZA151 ZA161 4C087 AA01 AA02 BB61 CA04 CA34 MA52 NA02 NA09 NA14 ZA15 ZA16 ─────────────────────────────────────────────────── ─── Continued front page (72) Inventor Nagahiro Yamazaki 9-5 Akahori Shinmachi, Yokkaichi-shi, Mie Solarization Gaku Co., Ltd. F-term (reference) 4B018 LB01 MD72 ME10 ME14 MF01 4B042 AC04 AD40 AG06 AG07 AH10 AP15 4C084 AA01 AA02 BA44 CA41 DC50 MA52 NA02 NA09 NA14 ZA151 ZA161 4C087 AA01 AA02 BB61 CA04 CA34 MA52 NA02 NA09 NA14 ZA15 ZA16
Claims (2)
特徴とする脳機能改善組成物。1. A brain function improving composition comprising an egg yolk plasma floating fraction.
ンを含むことを特徴とする請求項１記載の脳機能改善組
成物。2. The brain function improving composition according to claim 1, wherein the egg yolk plasma levitated fraction contains apoviterenin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002108290A JP4535662B2 (en) | 2002-04-10 | 2002-04-10 | Brain function improving composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002108290A JP4535662B2 (en) | 2002-04-10 | 2002-04-10 | Brain function improving composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003300891A true JP2003300891A (en) | 2003-10-21 |
| JP4535662B2 JP4535662B2 (en) | 2010-09-01 |
Family
ID=29392109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002108290A Expired - Lifetime JP4535662B2 (en) | 2002-04-10 | 2002-04-10 | Brain function improving composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4535662B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007108695A1 (en) * | 2006-03-22 | 2007-09-27 | Memoran As | Preparation for prophylactic or therapeutic treatment of lapse of memory |
| JP2007246404A (en) * | 2006-03-14 | 2007-09-27 | Snow Brand Milk Prod Co Ltd | Learning ability-improving agent |
| JPWO2008081934A1 (en) * | 2006-12-28 | 2010-04-30 | 明治乳業株式会社 | Infant brain development promoter containing milk-derived phospholipid and food composition containing the same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08266255A (en) * | 1995-03-30 | 1996-10-15 | Taiyo Kagaku Co Ltd | Composition for improving learning ability |
| JPH10201426A (en) * | 1997-01-18 | 1998-08-04 | Taiyo Kagaku Co Ltd | Method for fractionating egg yolk |
| JPH1180009A (en) * | 1997-09-12 | 1999-03-23 | Seiwa Yakuhin Kk | Agent for improving brain function and agent for preventing lowering of brain function |
| JP2001510803A (en) * | 1997-07-25 | 2001-08-07 | マイケル・アンソニー・フォラン | Maternal immunosecretion and its use in the treatment and / or prevention of conditions in the human body |
-
2002
- 2002-04-10 JP JP2002108290A patent/JP4535662B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08266255A (en) * | 1995-03-30 | 1996-10-15 | Taiyo Kagaku Co Ltd | Composition for improving learning ability |
| JPH10201426A (en) * | 1997-01-18 | 1998-08-04 | Taiyo Kagaku Co Ltd | Method for fractionating egg yolk |
| JP2001510803A (en) * | 1997-07-25 | 2001-08-07 | マイケル・アンソニー・フォラン | Maternal immunosecretion and its use in the treatment and / or prevention of conditions in the human body |
| JPH1180009A (en) * | 1997-09-12 | 1999-03-23 | Seiwa Yakuhin Kk | Agent for improving brain function and agent for preventing lowering of brain function |
Non-Patent Citations (3)
| Title |
|---|
| NIPPON SUISAN GAKKAISHI (2002), VOL.68, NO.5, P.719-722, JPN7008008963, ISSN: 0001628506 * |
| 応用糖質科学 (1995), VOL.42, NO.1, P.15-18, JPN6008064445, ISSN: 0001210040 * |
| 応用糖質科学 (1996), VOL.43, NO.2, P.283-287, JPN6008064446, ISSN: 0001210041 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007246404A (en) * | 2006-03-14 | 2007-09-27 | Snow Brand Milk Prod Co Ltd | Learning ability-improving agent |
| WO2007108695A1 (en) * | 2006-03-22 | 2007-09-27 | Memoran As | Preparation for prophylactic or therapeutic treatment of lapse of memory |
| JPWO2008081934A1 (en) * | 2006-12-28 | 2010-04-30 | 明治乳業株式会社 | Infant brain development promoter containing milk-derived phospholipid and food composition containing the same |
| JP5959137B2 (en) * | 2006-12-28 | 2016-08-02 | 株式会社明治 | Infant brain development promoter containing milk-derived phospholipid and food composition containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4535662B2 (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2554761C (en) | Neuroprotective dietary supplement | |
| JP6016363B2 (en) | Cranial nerve cell neoplasia | |
| RU2606841C2 (en) | Method and preparation for the treatment or prevention of anxiety or neurogenesis | |
| KR20100105598A (en) | Sense-improving agent | |
| US20120309716A1 (en) | Motor Function Improver | |
| JP2006273850A (en) | Suppression composition for lactic acid value elevation in blood, and food and drink comprising same | |
| EP2123666A1 (en) | Peptide | |
| JP2012232982A (en) | Method for regulating weight and size of animal with glycin | |
| WO2012143860A1 (en) | Ameliorating cognitive decline | |
| JP2003300891A (en) | Cerebral function ameliorating composition | |
| JP6158565B2 (en) | Muscle protein synthesis signal enhancer | |
| WO2021201128A1 (en) | Oral composition for enhancing expression or promoting production of ciliary neurotrophic factor, or for improving cognitive function | |
| KR20030036898A (en) | Compositions for improving lipid metabolism | |
| US20120122984A1 (en) | Methods of Treating Lipomas and Liposarcomas | |
| EP2797618A1 (en) | Preparation for improving memory and learning and use thereof | |
| WO2010134384A1 (en) | Skin function-improving composition | |
| JPH01299224A (en) | Promoter of cholesterol excretion, use and mixture thereof | |
| JPH10146166A (en) | Physiologically active composition | |
| US7919620B2 (en) | Agent for suppressing blood pressure elevation | |
| JPH06199693A (en) | Agent for amelioration and treatment of ischemic disease | |
| JP2003300890A (en) | Blood triglyceride level depressant | |
| Liao et al. | Buffalo Milk Can Rescue Fatigue in Young Mice, Alleviate Oxidative Stress and Boost Learning and Memory in Aging Mice | |
| RU2734921C1 (en) | Method for application of additive from bakery yeast saccharomyces cerevisiae to food in ration of athletes | |
| EP4049672A1 (en) | Muscle quality improvement agent | |
| JP2009126787A (en) | Sense-improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050404 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090713 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100528 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100615 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130625 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4535662 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |